Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons
Authors:
- 17 December 2016
- journal article
- review article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 34 (1) , 1-10
Abstract
Bone pain arising due to skeletal metastases is one of the common complications experienced by the majority of patients suffering from prostate, breast and lung cancer at the advanced stage of the disease. These patients are subjected to palliative care in order to improve the quality of their remaining life. With the gradually increasing number of cancer cases, palliation of metastatic bone pain is gaining importance. Bone-seeking radiopharmaceuticals play a pivotal role in the management of cancer pain, particularly in patients with multiple metastases, as these agents are proven to be effective in controlling the bone pain with minimum side effects. Although a plethora of such radiopharmaceuticals have been developed and evaluated in animal models, only a few are regularly used in clinics while some of these agents are at different stages of clinical evaluations. The present article describes only those bone-seeking radiopharmaceuticals, which have been reported to be clinically administered till date, along with their relative merits and drawbacks.Keywords
Funding Information
- Bhabha Atomic Research Centre
This publication has 98 references indexed in Scilit:
- Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeJournal of Clinical Medicine, 2014
- Phase 2 Study of a High Dose of 186Re-HEDP for Bone Pain Palliation in Patients with Widespread Skeletal MetastasesJournal of Nuclear Medicine Technology, 2013
- Practicality of Production of 32 P by Direct Neutron Activation for Its Utilization in Bone Pain Palliation as Na 3 [ 32 P]PO 4Cancer Biotherapy and Radiopharmaceuticals, 2013
- Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone diseaseCancer Management and Research, 2013
- Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective AnalysisJournal of Nuclear Medicine, 2011
- 170Tm-EDTMP: a potential cost-effective alternative to 89SrCl2 for bone pain palliationNuclear Medicine and Biology, 2009
- EANM procedure guideline for treatment of refractory metastatic bone painEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Management of bone metastases in cancer: A reviewCritical Reviews in Oncology/Hematology, 2005
- Selective extraction of naturally occurring radioactive Ra2+Chemical Society Reviews, 2005
- The development and in-vivo behavior of tin containing radiopharmaceuticals—I. Chemistry, preparation, and biodistribution in small animalsInternational Journal of Nuclear Medicine and Biology, 1985